Clinical Roundup OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer June 06, 2025Vol.51 No.22
Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
Drugs & Targets Clairity becomes the first FDA-authorized AI platform for breast cancer prediction June 06, 2025Vol.51 No.22
Drugs & Targets EC approves Adcetris for newly diagnosed Hodgkin lymphoma in combination with ECADD June 06, 2025Vol.51 No.22
Drugs & Targets China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer June 06, 2025Vol.51 No.22
Drugs & Targets Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S. June 06, 2025Vol.51 No.22
Conversation with The Cancer Letter We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James May 30, 2025Vol.51 No.21By Paul Goldberg
Pfizer seeks to improve breast cancer outcomes in Sub-Saharan AfricaWith help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries May 30, 2025Vol.51 No.21By Claire Marie Porter
Trials & Tribulations The other side of the patient portal: Reflections from a cancer center leader May 30, 2025Vol.51 No.21By Ruben A. Mesa
Trials & Tribulations Surviving cancer is often not a patient’s most challenging battle May 30, 2025Vol.51 No.21By Boris C. Pasche
